Stay updated with breaking news from Eden Klein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar...
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar...
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership...
Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s...